Sponsor of the Day:
Jerkmate
https://sagimet.com/
Home - Sagimet Biosciences
Apr 22, 2026 - We are a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic...
sagimet biosciences
https://thedermdigest.com/acne-pipeline-update-sagimet-to-start-phase-3-trial-of-denifanstat-in-the-us/
Acne Pipeline Update: Sagimet to Start Phase 3 Trial of Denifanstat in the US - The Dermatology...
Apr 27, 2026 - Sagimet Biosciences Inc. is planning to start a Phase 3 clinical trial of denifanstat in acne in the US during the second half of 2026.
phase 3 trialacnepipelineupdatesagimet
https://sagimet.com/fasn/
FASN - Sagimet Biosciences
May 1, 2026 - FASN is a key regulator of lipid synthesis its activity is increased in certain diseases such as in the liver and also been shown to play a role in...
sagimet biosciencesfasn
https://sagimet.com/about/board-of-directors/
Board of Directors FASN Products Company | Sagimet Biosciences
Apr 14, 2026 - David M. Mott is one of our board of directors of FASN products Company who joined New Enterprise Associates (NEA) in September 2008 as a General Partner...
products companysagimet biosciencesboarddirectorsfasn